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bstract
he American College of Cardiology Foundation (ACCF),
long with key specialty and subspecialty societies, con-
ucted an appropriate use review of common clinical sce-
arios where cardiac radionuclide imaging (RNI) is fre-
uently considered. This document is a revision of the
riginal Single-Photon Emission Computed Tomography
yocardial Perfusion Imaging (SPECT MPI) Appropri-
teness Criteria (1), published 4 years earlier, written to
eflect changes in test utilization and new clinical data, and
o clarify RNI use where omissions or lack of clarity existed
n the original criteria. This is in keeping with the commit-
ent to revise and refine appropriate use criteria (AUC) on
frequent basis.
The indications for this review were drawn from common
pplications or anticipated uses, as well as from current
linical practice guidelines. Sixty-seven clinical scenarios
ere developed by a writing group and scored by a separate
echnical panel on a scale of 1 to 9 to designate appropriate
se, inappropriate use, or uncertain use.
In general, use of cardiac RNI for diagnosis and risk
ssessment in intermediate- and high-risk patients with
oronary artery disease (CAD) was viewed favorably, while
esting in low-risk patients, routine repeat testing, and
eneral screening in certain clinical scenarios were viewed
ess favorably. Additionally, use for perioperative testing was
ound to be inappropriate except for high selected groups of
atients. It is anticipated that these results will have a
ignificant impact on physician decision making, test per-
ormance, and reimbursement policy, and will help guide
uture research.
reface
n an effort to respond to the need for the rational use of
maging services in the delivery of high quality care, the
CCF has undertaken a process to determine the appro-
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ndications.
Appropriate use criteria publications reflect an ongoing
ffort by the ACCF to critically and systematically create,
eview, and categorize clinical situations where diagnostic
ests and procedures are utilized by physicians caring for
atients with cardiovascular diseases. The process is based
n a current understanding of the technical capabilities of
he imaging modalities examined. Although not intended to
e entirely comprehensive, the indications are meant to
dentify common scenarios encompassing the majority of
ontemporary practice. Given the breadth of information
hey convey, the indications do not directly correspond to
he Ninth Revision of the International Classification of
iseases (ICD-9) system as these codes do not include
linical information, such as symptom status.
The ACCF believes that careful blending of a broad
ange of clinical experiences and available evidence-based
nformation will help guide a more efficient and equitable
llocation of health care resources in cardiovascular imaging.
he ultimate objective of AUC is to improve patient care
nd health outcomes in a cost-effective manner, but it is not
ntended to ignore ambiguity and nuance intrinsic to clinical
ecision making. Local parameters, such as the availability
r quality of equipment or personnel, may influence the
election of appropriate imaging procedures. Appropriate
se criteria thus should not be considered a substitute for
ound clinical judgment and practice experience.
The ACCF AUC process itself is also evolving. In the
urrent iteration, technical panel members were asked to
ate indications for cardiac RNI in a manner independent
nd irrespective of the prior published ACCF ratings for
PECT MPI (1) as well as the prior ACCF ratings for
imilar diagnostic stress imaging modalities, such as stress
chocardiography (2), cardiac computed tomography, or
ardiac magnetic resonance (3). Given the iterative nature of
he process, readers are counseled not to compare too closely
ndividual appropriate use ratings among modalities rated at
ifferent times over the past 2 years. Since this process is
terative and evolving, readers are counseled that individual
ppropriate use ratings among modalities rated at different
imes over the past 2 years may not be consistent. A
omparative evaluation of the appropriate use of multiple
maging techniques will be undertaken in the near future to
ssess the relative strengths of each modality for various
linical scenarios.
We are grateful to the technical panel, a professional
roup with a wide range of skills and insights, for their
houghtful and thorough deliberation on the merits of
ardiac RNI for various indications. In addition to our
hanks to the technical panel for their dedicated work and
eview, we would like to offer special thanks to the many
ndividuals who provided a careful review of the draft
ndications; to Peggy Christiansen, the ACCF librarian for
er comprehensive literature searches; to Lindsey Law and
ennedy Elliott, who continually drove the process forward; bnd to Robert Hendel, MD, the chair of the writing
ommittee, for his dedication, insight, and leadership.
Michael J. Wolk, MD, MACC
Moderator, Cardiac Radionuclide Imaging Technical Panel
Ralph G. Brindis, MD, MPH, FACC, FSCAI
Chair, Appropriate Use Criteria Task Force
. Introduction
his report addresses the appropriate use of cardiac RNI.
mprovements in cardiovascular imaging technology and
ts application, coupled with increasing therapeutic op-
ions for cardiovascular disease, have led to an increase in
ardiovascular imaging. At the same time, the armamen-
arium of noninvasive diagnostic tools has expanded with
nnovations in new contrast agents, molecular RNI,
erfusion echocardiography, computed tomography for
oronary angiography and calcium score, and magnetic
esonance imaging for myocardial structure and viability.
s the field of cardiac radionuclide cardiovascular imag-
ng continues to advance along with other imaging
odalities, the health care community needs to under-
tand how to best incorporate these technologies into
aily clinical care.
All prior AUC publications from the ACCF and
ollaborating organizations have reflected an ongoing
ffort to critically and systematically create, review, and
ategorize the appropriate use of certain cardiovascular
iagnostic tests. The American College of Cardiology
ecognizes the importance of revising these criteria in a
imely manner in order to provide the cardiovascular
ommunity with the most accurate indications. This
ocument presents the first attempt to update an existing
UC document, the 2005 published ACCF/ASNC Ap-
ropriateness Criteria for Single-Photon Emission Com-
uted Tomography Myocardial Perfusion Imaging
SPECT MPI) (1). Clinicians, payers, and patients are
nterested in the specific benefits of cardiac RNI. Impor-
antly, inappropriate use of cardiac RNI may be poten-
ially harmful to patients and generate unwarranted costs
o the healthcare system, whereas appropriate procedures
hould likely improve patients’ clinical outcomes. This is
critical shift since the intent is for the potential benefits
nd risks of the treatment to be explicitly considered,
ather than just the potential usefulness of a diagnostic
est as a prelude to further treatment. This document
resents the results of this effort, but it is critical to
nderstand the background and scope of this document
efore interpreting the rating tables.
. Methods
he indications included in this publication are purposefully
road, and comprise a wide array of cardiovascular signs and
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ardiovascular findings.
A detailed description of the methods used for ranking
he selected clinical indications is outlined in Appendix B
nd is also found more generally in a previous publication
ntitled, “ACCF Proposed Method for Evaluating the
ppropriateness of Cardiovascular Imaging” (4). Briefly,
his process combines evidence-based medicine and prac-
ice experience by engaging a technical panel in a
odified Delphi exercise. Since the original SPECT
ocument (1) and methods paper (4) were published,
everal important processes have been put in place to
urther enhance this process. They include convening a
ormal writing group with diverse expertise in imaging,
irculating the indications for external review prior to
ating by the technical panel, and ensuring appropriate
alance of the technical panel, a standardized rating
ackage, and formal roles for facilitating panel interac-
ion at the face-to-face meeting. These changes are
etailed in a separate manuscript, which is in preparation.
The panel first rated indications independently. Then the
anel was convened for a face-to-face meeting for discussion
f each indication. At this meeting, panel members were
rovided with their scores and a blinded summary of their
eers’ scores. After the consensus meeting, panel members
ere then asked to independently provide their final scores
or each indication.
While panel members were not provided explicit cost
nformation to help determine their appropriate use ratings,
hey were asked to implicitly consider cost as an additional
actor in their evaluation of appropriate use.
In developing these criteria, the AUC Technical Panel
as asked to assess whether the use of the test for each
ndication is appropriate, uncertain, or inappropriate, and
as provided the following definition of appropriate use:
An appropriate imaging study is one in which the expected
ncremental information, combined with clinical judgment,
xceeds the expected negative consequences* by a sufficiently
ide margin for a specific indication that the procedure is
enerally considered acceptable care and a reasonable ap-
roach for the indication.
The technical panel scores each indication as follows:
Score 7–9
Appropriate test for specific indication (test is generally
acceptable and is a reasonable approach for the
indication).
Score 4–6
Uncertain for specific indication (test may be generally
acceptable and may be a reasonable approach for the
indication). (Uncertainty also implies that more re-
Negative consequences include the risks of the procedure radiation or contrast
xposure and the downstream impact of poor test performance such as delay in
iagnosis (false negatives) or inappropriate diagnosis (false positives).search and/or patient information is needed to classify
the indication definitively.)
Score 1–3
Inappropriate test for that indication (test is not gener-
ally acceptable and is not a reasonable approach for
the indication).
The contributors acknowledge that the division of these
cores into 3 categories of appropriate use is somewhat
rbitrary and that the numeric designations should be
iewed as a continuum. The contributors also recognize
iversity in clinical opinion for particular clinical scenarios.
cores in the intermediate level of appropriate use should
herefore be labeled “uncertain,” as critical patient or re-
earch data may be lacking or discordant. This designation
hould be a prompt to the field to carry out definitive
esearch investigation whenever possible. It is anticipated
hat the AUC reports will require updates as further data are
enerated and information from the implementation of the
riteria is accumulated.
To prevent bias in the scoring process, the technical panel
as deliberately not comprised solely of specialists in the
articular procedure under evaluation. Specialists, while
ffering important clinical and technical insights, might
ave a natural tendency to rate the indications within their
pecialty as more appropriate than nonspecialists. In addi-
ion, care was taken in providing objective, nonbiased
nformation, including guidelines and key references, to the
echnical panel.
The level of agreement among panelists as defined by
AND (5) was analyzed based on the BIOMED rule for a
anel of 14 to 16 members. As such, agreement was defined
s an indication where 4 or fewer panelists’ ratings fell
utside the 3-point region containing the median score.
isagreement was defined as where at least 5 panelists’
atings fell in both the appropriate and the inappropriate
ategories. Any indication having disagreement was catego-
ized as uncertain regardless of the final median score.
ndications which met neither definition for agreement or
isagreement are in a third, unlabeled category.
. General Assumptions
o prevent any inconsistencies in interpretation, specific
ssumptions are provided that were considered by the
echnical panel in rating the relevant clinical indications for
he appropriate use of RNI:
. Panel members were to assume that all radionuclide
techniques with different radiopharmaceuticals and im-
aging protocols were available for each indication and
that each was performed in a manner similar to that
found in the published literature.
. Radionuclide imaging is performed in accordance with
best practice standards as delineated in the imaging
guidelines for nuclear cardiology procedures (6). It is also
34
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June 9, 2009:2201–29 Appropriate Use Criteria for Cardiac Radionuclide Imagingassumed that procedures are performed in an accredited
facility with appropriately credentialed physicians.
. Unless otherwise noted, all indications referred to
SPECT MPI and positron emission tomography myo-
cardial perfusion imaging. All radionuclide perfusion
imaging indications also assume the use of electrocardio-
gram (ECG) gating, whenever possible, with determi-
nation of global ventricular function (i.e., left ventricular
ejection fraction) and regional wall motion as part of the
evaluation.
. For all stress imaging, the mode of stress testing was
assumed to be exercise for patients able to exercise. For
patients unable to exercise, pharmacologic stress testing
was assumed to be used. Further background on the
rationale for the assumption of exercise testing is avail-
able in the ACC/AHA 2002 Guideline Update for
Exercise Testing (7).
. In the setting of a known acute coronary syndrome
(ACS), the use of stress testing should be performed in
conjunction with pharmacologic stress testing, not exercise.
. The use of testing in the perioperative setting is assumed
to have the potential to impact clinical decision making
and to direct therapeutic interventions.
. The category of “uncertain” should be used when insuf-
ficient clinical data is available for a definitive categori-
zation or there is substantial disagreement regarding the
appropriateness of that indication. The designation of
“uncertain” is assumed to not provide grounds for denial
of reimbursement.
. Definitions
complete set of definitions of terms used throughout the
ndication set are listed in Appendix A. These definitions
ere provided and discussed with the technical panel prior
o ratings of indications.
Ischemic Equivalent: Chest Pain Syndrome, Anginal
quivalent, or Ischemic ECG Abnormalities: Any con-
tellation of clinical findings that the physician feels is
onsistent with obstructive CAD. Examples of such find-
ngs include, but are not exclusive to, chest pain, chest
ightness, burning, shoulder pain, palpitations, jaw pain,
nd new ECG abnormalities suggestive of ischemic heart
isease. Non-chest pain symptoms, such as dyspnea or
orsening effort tolerance, that are felt to be consistent with
AD may also be considered to be an anginal equivalent.
etermining Pretest Risk Assessment for
isk Stratification
isk Assessment for Asymptomatic Patients
The indications on risk assessment include asymptomatic
atients with suspected CAD. It is assumed that clinicians
ill use RNI studies in addition to standard methods of risk
ssessment as presented in the National Heart, Lung, and
lood Institute report on “Detection, Evaluation, and
t
freatment of High Blood Cholesterol in Adults (Adult
reatment Panel III)” (ATP III) (8).
oronary Heart Disease (CHD) Risk (Based on the ACC/AHA
cientific Statement on Cardiovascular Risk Assessment [9])
bsolute risk is defined as the probability of developing
HD, including myocardial infarction or CHD death
ver a given time period. The ATP III report specifies
bsolute risk for CHD over the next 10 years. CHD risk
efers to 10-year risk for any hard cardiac event.
CHD Risk—Low
Defined by the age-specific risk level that is below
average. In general, low risk will correlate with a 10-year
absolute CHD risk less than 10%.
CHD Risk—Moderate
Defined by the age-specific risk level that is average or
above average. In general, moderate risk will correlate
with a 10-year absolute CHD risk between 10% and
20%.
CHD Risk—High†
Defined as the presence of diabetes mellitus in a
patient 40 years of age or older, peripheral arterial disease
or other coronary risk equivalents, or a 10-year absolute
CHD risk of greater than 20%.
Pretest Probability of CAD for Symptomatic (Ischemic
quivalent) Patients: Once the physician determines the
resence of symptoms that may represent obstructive CAD
ischemic equivalent present), the pretest probability of
AD should be assessed. There are a number of risk
lgorithms (10,11) available that can be used to calculate
his probability. Clinicians should become familiar with
hose algorithms that pertain to the populations they en-
ounter most often. In scoring the indications, the following
robabilities, as calculated from any of the various available
lgorithms, should be applied.
Very low pretest probability: Less than 5% pretest
probability of CAD
Low pretest probability: Less than 10% pretest proba-
bility of CAD
Intermediate pretest probability: Between 10% and
90% pretest probability of CAD
High pretest probability: Greater than 90% pretest
probability of CAD
The method recommended by the ACC/AHA Guide-
ines for Chronic Stable Angina (12) is provided below as
ne example of a method used to calculate pretest proba-
ility and is a modification of a previously published
Grundy et al. (9) cites Framingham when assigning patients with diabetes mellitus
o a category of high short-term risk because these patients typically have multiple risk
actors and have poor prognoses if they develop CHD.
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Appropriate Use Criteria for Cardiac Radionuclide Imaging June 9, 2009:2201–29iterature review (13). Please refer to definitions of angina
nd to Table A. Please note that Table A only predicts
retest probability in patients without other complicating
istory or ECG findings. History and electrocardiographic
vidence of prior infarction dramatically affect pretest prob-
bility. While not incorporated into the algorithm, CAD
isk factors, discussed in the previous section, Determining
retest Risk Assessment for Risk Stratification, may also
ffect pretest likelihood of CAD. Detailed nomograms are
vailable that incorporate the effects of a history of prior
nfarction, electrocardiographic Q waves, electrocardio-
raphic ST- and T-wave changes, diabetes, smoking, and
ypercholesterolemia (14).
. Abbreviations
CS  acute coronary syndrome
ABG  coronary artery bypass grafting surgery
AD  coronary artery disease
HD  coronary heart disease
T  computed tomography
CG  electrocardiogram
RNA  equilibrium radionuclide angiography
P  First Pass
F  heart failure
BBB  left bundle-branch block
V  left ventricular
ET  estimated metabolic equivalents of exercise
I  myocardial infarction
PI  myocardial perfusion imaging
CI  percutaneous coronary intervention
ET  positron emission tomography
able A. Pretest Probability of CAD by Age, Gender, and Symp
Age
(Years) Gender
Typical/Definite
Angina Pectoris
39 Men Intermediate
Women Intermediate
40–49 Men High
Women Intermediate
50–59 Men High
Women Intermediate
60 Men High
Women High
igh: Greater than 90% pretest probability. Intermediate: Between 10% and 90% pretest probabili
rom the ACC/AHA Exercise Testing Guidelines to reflect all age ranges (14).NA  radionuclide angiography cNI  radionuclide imaging
PECT  single photon emission computed tomography
TEMI  ST-elevation myocardial infarction
A/NSTEMI  unstable angina (UA) and non–ST-
levation myocardial infarction (NSTEMI)
. Results of Ratings
he final ratings for cardiac RNI (Tables 1 to 8) are listed
y indication sequentially as obtained from second-round
ating sheets submitted by each panelist. The final score
eflects the median score of the 15 panelists and has been
abeled according to the 3 appropriate use categories of
ppropriate, uncertain, and inappropriate. Tables 9 to 11
resent the indications by these categories.
There was generally less variation in ratings for the
ndications labeled as either appropriate or inappropriate,
ith 73% and 64%, respectively, showing agreement as
efined in Section 2, Methods. There was, however,
reater variability (less agreement) in the rating scores for
ndications defined as uncertain, with 11% showing
greement as defined above, suggesting greater variation
n opinion. Two indications, 26 and 28, were distributed
nto each extreme such that the panel was classified as
eing in disagreement. However, these indications were
lready placed in the uncertain category so no changes
ere required to reflect disagreement. Across all catego-
ies, several indications failed to meet the definition of
greement. In such cases, the final distribution of scores
cross the panel contained a greater diversity of scores
mong panel members, but the scores were not so
ivergent (as defined by disagreement) as to necessitate a
*
typical/Probable
Angina Pectoris
Nonanginal
Chest Pain Asymptomatic
Intermediate Low Very low
Very low Very low Very low
Intermediate Intermediate Low
Low Very low Very low
Intermediate Intermediate Low
Intermediate Low Very low
Intermediate Intermediate Low
Intermediate Intermediate Low
Between 5% and 10% pretest probability. Very low: Less than 5% pretest probability. *Modifiedtoms
A
ty. Low:hange in the final score.
7T
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able 1. Detection of CAD: Symptomatic
Indication
Appropriate Use
Score (1–9)
Evaluation of Ischemic Equivalent (Non-Acute)
1. ● Low pretest probability of CAD
● ECG interpretable AND able to exercise
I (3)
2. ● Low pretest probability of CAD
● ECG uninterpretable OR unable to exercise
A (7)
3. ● Intermediate pretest probability of CAD
● ECG interpretable AND able to exercise
A (7)
4. ● Intermediate pretest probability of CAD
● ECG uninterpretable OR unable to exercise
A (9)
5. ● High pretest probability of CAD
● Regardless of ECG interpretability and ability to exercise
A (8)
Acute Chest Pain
6. ● Possible ACS
● ECG—no ischemic changes or with LBBB or electronically ventricular paced rhythm
● Low-risk TIMI score
● Peak troponin: borderline, equivocal, minimally elevated
A (8)
7. ● Possible ACS
● ECG—no ischemic changes or with LBBB or electronically ventricular paced rhythm
● High-risk TIMI score
● Peak troponin: borderline, equivocal, minimally elevated
A (7)
8. ● Possible ACS
● ECG—no ischemic changes or with LBBB or electronically ventricular paced rhythm
● Low-risk TIMI score
● Negative peak troponin levels
A (8)
9. ● Possible ACS
● ECG—no ischemic changes or with LBBB or electronically ventricular paced rhythm
● High-risk TIMI score
● Negative peak troponin levels
A (8)
10. ● Definite ACS* I (1)
Acute Chest Pain (Rest Imaging Only)
11. ● Possible ACS
● ECG—no ischemic changes or with LBBB or electronically ventricular paced rhythm
● Initial troponin negative
● Recent or ongoing chest pain
A (7)
See definition of ACS in Appendix A (based on ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction) (24).
TT
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Indication
Appropriate Use
Score (1–9)
Asymptomatic
12. ● Low CHD risk (ATP III risk criteria) I (1)
13. ● Intermediate CHD risk (ATP III risk criteria)
● ECG interpretable
I (3)
14. ● Intermediate CHD risk (ATP III risk criteria)
● ECG uninterpretable
U (5)
15. ● High CHD risk (ATP III risk criteria) A (7)
New-Onset or Newly Diagnosed Heart Failure With LV Systolic Dysfunction Without Ischemic Equivalent
16. ● No prior CAD evaluation AND no planned coronary angiography A (8)
New-Onset Atrial Fibrillation
17. ● Part of evaluation when etiology unclear U (6)
Ventricular Tachycardia
18. ● Low CHD risk (ATP III risk criteria) A (7)
19. ● Intermediate or high CHD risk (ATP III risk criteria) A (8)
Syncope
20. ● Low CHD risk (ATP III risk criteria) I (3)
21. ● Intermediate or high CHD risk (ATP III risk criteria) A (7)
Elevated Troponin
22. ● Troponin elevation without additional evidence of acute coronary syndrome A (7)able 3. Risk Assessment With Prior Test Results and/or Known Chronic Stable CAD
Indication
Appropriate Use
Score (1–9)
Asymptomatic OR Stable Symptoms
Normal Prior Stress Imaging Study
23. ● Low CHD risk (ATP III risk criteria)
● Last stress imaging study done less than 2 years ago
I (1)
24. ● Intermediate to high CHD risk (ATP III risk criteria)
● Last stress imaging study done less than 2 years ago
I (3)
25. ● Low CHD risk (ATP III risk criteria)
● Last stress imaging study done more than or equal to 2 years ago
I (3)
26. ● Intermediate to high CHD risk (ATP III risk criteria)
● Last stress imaging study done more than or equal to 2 years ago
U (6)
Asymptomatic OR Stable Symptoms
Abnormal Coronary Angiography OR Abnormal Prior Stress Imaging Study, No Prior Revascularization
27. ● Known CAD on coronary angiography OR prior abnormal stress imaging study
● Last stress imaging study done less than 2 years ago
I (3)
28. ● Known CAD on coronary angiography OR prior abnormal stress imaging study
● Last stress imaging study done more than or equal to 2 years ago
U (5)
Prior Noninvasive Evaluation
29. ● Equivocal, borderline, or discordant stress testing where obstructive CAD remains a concern A (8)
New or Worsening Symptoms
30. ● Abnormal coronary angiography OR abnormal prior stress imaging study A (9)
31. ● Normal coronary angiography OR normal prior stress imaging study U (6)
Coronary Angiography (Invasive or Noninvasive)
32. ● Coronary stenosis or anatomic abnormality of uncertain significance A (9)
Asymptomatic
Prior Coronary Calcium Agatston Score
33. ● Agatston score less than 100 I (2)
34. ● Low to intermediate CHD risk
● Agatston score between 100 and 400
U (5)
35. ● High CHD risk
● Agatston score between 100 and 400
A (7)
36. ● Agatston score greater than 400 A (7)
Duke Treadmill Score
37. ● Low-risk Duke treadmill score I (2)
38. ● Intermediate-risk Duke treadmill score A (7)
39. ● High-risk Duke treadmill score A (8)
T*
T
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June 9, 2009:2201–29 Appropriate Use Criteria for Cardiac Radionuclide Imagingable 4. Risk Assessment: Preoperative Evaluation for Noncardiac Surgery Without Active Cardiac Conditions*
Indication
Appropriate Use
Score (1–9)
Low-Risk Surgery
40. ● Preoperative evaluation for noncardiac surgery risk assessment I (1)
Intermediate-Risk Surgery
41. ● Moderate to good functional capacity (greater than or equal to 4 METs) I (3)
42. ● No clinical risk factors† I (2)
43. ● Greater than or equal to 1 clinical risk factor
● Poor or unknown functional capacity (less than 4 METs)
A (7)
44. ● Asymptomatic up to 1 year postnormal catheterization, noninvasive test, or previous revascularization I (2)
Vascular Surgery
45. ● Moderate to good functional capacity (greater than or equal to 4 METs) I (3)
46. ● No clinical risk factors† I (2)
47. ● Greater than or equal to 1 clinical risk factor
● Poor or unknown functional capacity (less than 4 METS)
A (8)
48. ● Asymptomatic up to 1 year postnormal catheterization, noninvasive test, or previous revascularization I (2)Refer to Table A1. †Refer to Table A2.able 5. Risk Assessment: Within 3 Months of an Acute Coronary Syndrome
Indication
Appropriate Use
Score (1–9)
STEMI
49. ● Primary PCI with complete revascularization
● No recurrent symptoms
I (2)
50. ● Hemodynamically stable, no recurrent chest pain symptoms or no signs of HF
● To evaluate for inducible ischemia
● No prior coronary angiography
A (8)
51. ● Hemodynamically unstable, signs of cardiogenic shock, or mechanical complications I (1)
UA/NSTEMI
52. ● Hemodynamically stable, no recurrent chest pain symptoms or no signs of HF
● To evaluate for inducible ischemia
● No prior coronary angiography
A (9)
ACS–Asymptomatic Postrevascularization (PCI or CABG)
53. ● Evaluation prior to hospital discharge I (1)
Cardiac Rehabilitation
54. ● Prior to initiation of cardiac rehabilitation (as a stand-alone indication) I (3)
T*
T
T
*
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Appropriate Use Criteria for Cardiac Radionuclide Imaging June 9, 2009:2201–29able 6. Risk Assessment: Postrevascularization (Percutaneous Coronary Intervention or Coronary Artery Bypass Graft)*
Indication
Appropriate Use
Score (1–9)
Symptomatic
55. ● Evaluation of ischemic equivalent A (8)
Asymptomatic
56. ● Incomplete revascularization
● Additional revascularization feasible
A (7)
57. ● Less than 5 years after CABG U (5)
58. ● Greater than or equal to 5 years after CABG A (7)
59. ● Less than 2 years after PCI I (3)
60. ● Greater than or equal to 2 years after PCI U (6)
Cardiac Rehabilitation
61. ● Prior to initiation of cardiac rehabilitation (as a stand-alone indication) I (3)In patients who have had multiple coronary revascularization procedures, consider the most recent procedure.able 7. Assessment of Viability/Ischemia
Indication
Appropriate Use
Score (1–9)
Ischemic Cardiomyopathy/Assessment of Viability
62. ● Known severe LV dysfunction
● Patient eligible for revascularization
A (9)able 8. Evaluation of Ventricular Function
Indication
Appropriate Use
Score (1–9)
Evaluation of LV Function
63. ● Assessment of LV function with radionuclide angiography (ERNA or FP RNA)
● In absence of recent reliable diagnostic information regarding ventricular function obtained with
another imaging modality
A (8)
64. ● Routine* use of rest/stress ECG-gating with SPECT or PET MPI A (9)
65. ● Routine* use of stress FP RNA in conjunction with rest/stress gated SPECT MPI I (3)
66. ● Selective use of stress FP RNA in conjunction with rest/stress gated SPECT MPI
● Borderline, mild, or moderate stenoses in 3 vessels OR moderate or equivocal left main stenosis in
left dominant system
U (6)
Use of Potentially Cardiotoxic Therapy (e.g., Doxorubicin)
67. ● Serial assessment of LV function with radionuclide angiography (ERNA or FP RNA)
● Baseline and serial measures after key therapeutic milestones or evidence of toxicity
A (9)Performed under most clinical circumstances, except in cases with technical inability or clear-cut redundancy of information.
8T
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able 9. Appropriate Indications (Median Score 7–9)
Indication
Appropriate Use
Score (1–9)
Detection of CAD: Symptomatic
Evaluation of Ischemic Equivalent (Nonacute)
2. ● Low pretest probability of CAD
● ECG uninterpretable OR unable to exercise
A (7)
3. ● Intermediate pretest probability of CAD
● ECG interpretable AND able to exercise
A (7)
4. ● Intermediate pretest probability of CAD
● ECG uninterpretable OR unable to exercise
A (9)
5. ● High pretest probability of CAD
● Regardless of ECG interpretability and ability to exercise
A (8)
Detection of CAD: Symptomatic
Acute Chest Pain
6. ● Possible ACS
● ECG—no ischemic changes or with LBBB or electronically ventricular paced rhythm
● Low-risk TIMI score
● Peak troponin: borderline, equivocal, minimally elevated
A (8)
7. ● Possible ACS
● ECG—no ischemic changes or with LBBB or electronically ventricular paced rhythm
● High-risk TIMI score
● Peak troponin: borderline, equivocal, minimally elevated
A (7)
8. ● Possible ACS
● ECG—no ischemic changes or with LBBB or electronically ventricular paced rhythm
● Low-risk TIMI score
● Negative peak troponin levels
A (8)
9. ● Possible ACS
● ECG—no ischemic changes or with LBBB or electronically ventricular paced rhythm
● High-risk TIMI score
● Negative peak troponin levels
A (8)
Detection of CAD: Symptomatic
Acute Chest Pain (Rest Imaging Only)
11. ● Possible ACS
● ECG—no ischemic changes or with LBBB or electronically ventricular paced rhythm
● Initial troponin negative
● Recent or ongoing chest pain
A (7)
Detection of CAD/Risk Assessment: Without Ischemic Equivalent
Asymptomatic
15. ● High CHD risk (ATP III risk criteria) A (7)
Detection of CAD/Risk Assessment: Without Ischemic Equivalent
New-Onset or Newly Diagnosed Heart Failure With LV Systolic Dysfunction Without Ischemic Equivalent
16. ● No prior CAD evaluation AND no planned coronary angiography A (8)
Detection of CAD/Risk Assessment: Without Ischemic Equivalent
Ventricular Tachycardia
18. ● Low CHD risk (ATP III risk criteria) A (7)
19. ● Intermediate or high CHD risk (ATP III risk criteria) A (8)
Detection of CAD/Risk Assessment: Without Ischemic Equivalent
Syncope
21. ● Intermediate or high CHD risk (ATP III risk criteria) A (7)
Detection of CAD/Risk Assessment: Without Ischemic Equivalent
Elevated Troponin
22. ● Troponin elevation without additional evidence of acute coronary syndrome A (7)
Risk Assessment With Prior Test Results and/or Known Chronic Stable CAD
Prior Noninvasive Evaluation
29. ● Equivocal, borderline, or discordant stress testing where obstructive CAD remains a concern A (8)
Risk Assessment With Prior Test Results and/or Known Chronic Stable CAD
New or Worsening Symptoms
30. ● Abnormal coronary angiography OR abnormal prior stress imaging study A (9)
T*
t
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Indication
Appropriate Use
Score (1–9)
Risk Assessment With Prior Test Results and/or Known Chronic Stable CAD
Coronary Angiography (Invasive or Noninvasive)
32. ● Coronary stenosis or anatomic abnormality of uncertain significance A (9)
Risk Assessment with Prior Test Results and/or Known Chronic Stable CAD
Asymptomatic
Prior Coronary Calcium Agatston Score
35. ● High CHD risk
● Agatston score between 100 and 400
A (7)
36. ● Agatston score greater than 400 A (7)
Risk Assessment with Prior Test Results and/or Known Chronic Stable CAD
Duke Treadmill Score
38. ● Intermediate-risk Duke treadmill score A (7)
39. ● High-risk Duke treadmill score A (8)
Risk Assessment: Preoperative Evaluation for Noncardiac Surgery Without Active Cardiac Conditions*
Intermediate-Risk Surgery
43. ● Greater than or equal to 1 clinical risk factor
● Poor or unknown functional capacity (less than 4 METS)
A (7)
Risk Assessment: Preoperative Evaluation for Noncardiac Surgery Without Active Cardiac Conditions*
Vascular Surgery
47. ● Greater than or equal to 1 clinical risk factor
● Poor or unknown functional capacity (less than 4 METS)
A (8)
Risk Assessment: Within 3 Months of an ACS
STEMI
50. ● Hemodynamically stable, no recurrent chest pain symptoms or no signs of HF
● To evaluate for inducible ischemia
● No prior coronary angiography
A (8)
Risk Assessment: Within 3 Months of an ACS
UA/NSTEMI
52. ● Hemodynamically stable, no recurrent chest pain symptoms or no signs of HF
● To evaluate for inducible ischemia
● No prior coronary angiography
A (9)
Risk Assessment: Postrevascularization (PCI or CABG)†
Symptomatic
55. ● Evaluation of ischemic equivalent A (8)
Risk Assessment: Postrevascularization (PCI or CABG)†
Asymptomatic
56. ● Incomplete revascularization
● Additional revascularization feasible
A (7)
58. ● Greater than or equal to 5 years after CABG A (7)
Assessment of Viability/Ischemia
Ischemic Cardiomyopathy/Assessment of Viability
62. ● Known severe LV dysfunction
● Patient eligible for revascularization
A (9)
Evaluation of Ventricular Function
Evaluation of LV Function
63. ● Assessment of LV function with radionuclide angiography (ERNA or FP RNA)
● In absence of recent reliable diagnostic information regarding ventricular function obtained with
another imaging modality
A (8)
64. ● Routine‡ use of rest/stress ECG-gating with SPECT or PET MPI A (9)
Evaluation of Ventricular Function
Use of Potentially Cardiotoxic Therapy (e.g., Doxorubicin)
67. ● Serial assessment of LV function with radionuclide angiogram (ERNA or FP RNA)
● Baseline and serial measures after key therapeutic milestones or evidence of toxicity
A (9)See Table A1. †In patients who have had multiple coronary revascularization procedures, consider the most recent procedure. ‡Performed under most clinical circumstances, except in cases with
echnical inability, or clear-cut redundancy of information.
T*
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Indication
Appropriate Use
Score (1–9)
Detection of CAD/Risk Assessment Without Ischemic Equivalent
Asymptomatic
14. ● Intermediate CHD risk (ATP III risk criteria)
● ECG uninterpretable
U (5)
Detection of CAD/Risk Assessment Without Ischemic Equivalent
New-Onset Atrial Fibrillation
17. ● Part of evaluation when etiology unclear U (6)
Risk Assessment With Prior Test Results and/or Known Chronic Stable CAD
Asymptomatic OR Stable Symptoms
Normal Prior Stress Imaging Study
26. ● Intermediate to high CHD risk (ATP III risk criteria)
● Last stress imaging study done more than or equal to 2 years ago
U (6)
Risk Assessment With Prior Test Results and/or Known Chronic Stable CAD
Asymptomatic OR Stable Symptoms
Abnormal Coronary Angiography OR Abnormal Prior Stress Imaging Study,
No Prior Revascularization
28. ● Poor exercise tolerance (less than or equal to 4 METs)
● Intermediate clinical risk predictors
U (5)
Risk Assessment With Prior Test Results and/or Known Chronic Stable CAD
New or Worsening Symptoms
31. ● Normal coronary angiography OR normal prior stress imaging study U (6)
Risk Assessment With Prior Test Results and/or Known Chronic Stable CAD
Asymptomatic
Prior Coronary Calcium Agatston Score
34. ● Low to intermediate CHD risk
● Agatston score between 100 and 400
U (5)
Risk Assessment: Postrevascularization (PCI or CABG)*
Asymptomatic
57. ● Less than 5 years after CABG U (5)
60. ● Greater than or equal to 2 years after PCI U (6)
Evaluation of Ventricular Function
Evaluation of Left Ventricular Function
66. ● Selective use of stress FP RNA in conjunction with rest/stress gated SPECT MPI
● Borderline, mild, or moderate stenoses in 3 vessels OR moderate or equivocal left main stenosis in
left dominant system
U (6)In patients who have had multiple coronary revascularization procedures, consider the most recent procedure.
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Indication
Appropriate Use
Score (1–9)
Detection of CAD: Symptomatic
Evaluation of Ischemic Equivalent (Nonacute)
1. ● Low pretest probability of CAD
● ECG interpretable AND able to exercise
I (3)
Detection of CAD: Symptomatic
Acute Chest Pain
10. ● Definite ACS* I (1)
Detection of CAD/Risk Assessment Without Ischemic Equivalent
Asymptomatic
12. ● Low CHD risk (ATP III risk criteria) I (1)
13. ● Intermediate CHD risk (ATP III risk criteria)
● ECG interpretable
I (3)
Detection of CAD/Risk Assessment Without Ischemic Equivalent
Syncope
20. ● Low CHD risk (ATP III risk criteria) I (3)
Risk Assessment With Prior Test Results and/or Known Chronic Stable CAD
Asymptomatic OR Stable Symptoms
Normal Prior Stress Imaging Study
23. ● Low CHD risk (ATP III risk criteria)
● Last stress imaging study done less than 2 years ago
I (1)
24. ● Intermediate to high CHD risk (ATP III risk criteria)
● Last stress imaging study done less than 2 years ago
I (3)
25. ● Low CHD risk (ATP III risk criteria)
● Last stress imaging study done more than or equal to 2 years ago
I (3)
Risk Assessment With Prior Test Results and/or Known Chronic Stable CAD
Asymptomatic OR Stable Symptoms
Abnormal Coronary Angiography OR Abnormal Prior Stress Imaging Study,
No Prior Revascularization
27. ● Known CAD on coronary angiography OR prior abnormal stress imaging study
● Last stress imaging study done less than 2 years ago
I (3)
Risk Assessment With Prior Test Results and/or Known Chronic Stable CAD
Asymptomatic
Prior Coronary Calcium Agatston Score
33. ● Agatston score less than 100 I (2)
Risk Assessment With Prior Test Results and/or Known Chronic Stable CAD
Duke Treadmill Score
37. ● Low-risk Duke treadmill score I (2)
Risk Assessment: Preoperative Evaluation for Noncardiac Surgery Without Active Cardiac Conditions*
Low-Risk Surgery
40. ● Preoperative evaluation for noncardiac surgery risk assessment I (1)
Risk Assessment: Preoperative Evaluation for Noncardiac Surgery Without Active Cardiac Conditions*
Intermediate-Risk Surgery
41. ● Moderate to good functional capacity (greater than or equal to 4 METs) I (3)
42. ● No clinical risk factors† I (2)
44. ● Asymptomatic up to 1 year postnormal catheterization, noninvasive test, or previous revascularization I (2)
Risk Assessment: Preoperative Evaluation for Noncardiac Surgery Without Active Cardiac Conditions*
Vascular Surgery
45. ● Moderate to good functional capacity (greater than or equal to 4 METs) I (3)
46. ● No clinical risk factors† I (2)
48. ● Asymptomatic up to 1 year postnormal catheterization, noninvasive test, or previous revascularization I (2)
Risk Assessment: Within 3 Months of an ACS
STEMI
49. ● Primary PCI with complete revascularization
● No recurrent symptoms
I (2)
51. ● Hemodynamically unstable, signs of cardiogenic shock, or mechanical complications I (1)
Risk Assessment: Within 3 Months of an ACS
ACS–Asymptomatic Postrevascularization (PCI or CABG)
53. ● Evaluation prior to hospital discharge I (1)
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his document is a revision of the original SPECT MPI
ppropriateness Criteria (1) published 4 years earlier, writ-
en to reflect changes in test utilization, to add insight
rovided by interim clinical data, and to clarify cardiac RNI
se where omissions or lack of clarity existed in the original
riteria. This is consistent with the commitment to revise
nd refine AUC on a frequent basis. Published trials and a
ocietal review have highlighted a significant number of
linical scenarios that were either uncertain or could not be
ategorized with the original criteria and warranted recon-
ideration (15–17). Additionally, trials and reviews have
uggested new clinical indications to consider for this
pdate of AUC for RNI.
In addition to adding new clinical indications and clari-
ying existing indications from the original SPECT MPI
ppropriateness Criteria (1) document, the writing group,
echnical panel, and/or external reviewers of the RNI
ocument also revised specific definitions and assumptions.
our additional assumptions were added. The first ad-
ressed accordance with best practice standards as delin-
ated in the imaging guidelines for nuclear cardiology
rocedures (6) as well as ensuring that procedures are
erformed in an accredited facility. The second new as-
umption addressed the use of pharmacologic stress testing
ersus exercise stress testing in the setting of an ACS. The
hird new assumption emphasized that in the perioperative
etting, the use of RNI would have the potential to impact
linical decision making and to direct therapeutic interven-
ions. This assumption was added to enhance consistency
ith the updated 2007 ACC/AHA Guideline for Periop-
rative Cardiovascular Evaluation and Care for Noncardiac
urgery (18). The fourth new assumption addressed the
ategory of uncertain indications and clarified the relation-
hip between such a rating and grounds for reimbursement.
The writing group also revised the definition of “chest
able 11. Continued
Indication
Risk Assessment: W
Cardiac R
54. ● Prior to initiation of cardiac rehabilitation (as a stan
Risk Assessment: Postrev
Asym
59. ● Less than 2 years after PCI
Risk Assessment: Postrev
Cardiac R
61. ● Prior to initiation of cardiac rehabilitation (as a stan
Evaluation of V
Evaluation
65. ● Routine§ use of stress FP RNA in conjunction with
Refer to Table A1. †Refer to Table A2. ‡In patients who have had multiple coronary revasculariz
xcept in cases with technical inability, or clear-cut redundancy of information.ain syndrome” that had caused confusion when applying ahe original SPECT MPI document. The original defini-
ion of chest pain syndrome focused only on symptoms and
xcluded other clinical findings, such as new ECG changes
hat suggest the presence of obstructive CAD and may
arrant RNI testing. Therefore, a new term “ischemic
quivalent” was developed to encompass chest pain syn-
romes as well as other symptoms and signs that the
linician believes may be due to obstructive CAD. This
evision was supported by the writing group, technical
anel, and external reviewers.
The AUC in this report provide an estimate of whether
t is reasonable to use cardiac RNI for a particular clinical
cenario, such as those 67 indications listed in this docu-
ent. These criteria are expected to be useful for clinicians,
ealth care facilities, and third-party payers engaged in the
elivery of cardiovascular imaging. Experience with already
ublished AUC (1–3) has shown their value across a broad
ange of situations, guiding care of individual patients,
ducating caregivers, and informing policy decisions regard-
ng reimbursement for cardiovascular imaging.
Appropriate use criteria represent the first component of
he chain of quality recommendations for cardiovascular
maging (19). After ensuring proper test selection, the
chievement of quality in imaging includes adherence to
est practices in image acquisition, image interpretation and
esults communication, as well as incorporation of findings
nto clinical care. All components are important for optimal
atient care, although not addressed in this report. The
evelopment of AUC and their ranking by the technical
anel assumes that other quality standards have been met.
Although these criteria are intended to provide guidance
or patients and clinicians, they are not intended to serve as
ubstitutes for sound clinical judgment and practice experi-
nce. The writing group recognizes that many patients
ncountered in clinical practice may not be represented in
hese AUC or may have extenuating features when com-
ared with the clinical scenarios presented. Although the
Appropriate Use
Score (1–9)
Months of an ACS
ilitation
e indication) I (3)
arization (PCI or CABG)*
atic
I (3)
arization (PCI or CABG)‡
ilitation
e indication) I (3)
ular Function
Function
tress gated SPECT MPI I (3)
rocedures, consider the most recent procedure. §Performed under most clinical circumstances,ithin 3
ehab
d-alon
ascul
ptom
ascul
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rest/sppropriate use ratings reflect critical medical literature as
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Appropriate Use Criteria for Cardiac Radionuclide Imaging June 9, 2009:2201–29ell as expert consensus, physicians and other stakeholders
hould understand the role of clinical judgment in deter-
ining whether to order a test for an individual patient.
dditionally, uncertain indications often require individual
hysician judgment and understanding of the patient to
etter determine the usefulness of a test for a particular
cenario. As such, the ranking of an indication as uncertain
4 to 6) should not be viewed as limiting the use of cardiac
NI for such patients. It should be emphasized that the
echnical panel was instructed that the “uncertain” designa-
ion was still designed to be considered as a “reimbursable”
ategory.
These ratings are intended to evaluate the appropriate use
f specific patient scenarios to determine overall patterns of
are regarding cardiac RNI. In situations where there is
ubstantial variation between the appropriate use rating and
hat the clinician believes is the best recommendation for
he patient, further considerations or actions, such as a
econd opinion, may be appropriate. Moreover, it is not
nticipated that all physicians or facilities will have 100% of
heir cardiac radionuclide procedures deemed appropriate.
owever, related to the overall patterns of care, if the
ational average of appropriate and uncertain ratings is 80%,
or example, and a physician or facility has a 40% rate of
nappropriate procedures, further examination of the pat-
erns of care may be warranted and helpful.
Panelists were asked specifically to rate each indication
ccording to the definition of appropriate use (see Section 2,
ethods) and to not necessarily consider comparisons to
ther imaging procedures or other AUC documents while
ompleting their ratings, However, panelists were also
rovided with links to relevant guideline recommendations
s well as previously published AUC documents to ensure
hey were adequately educated on all relevant medical
iterature when rating the indications. Whereas the newer
odalities of CCTA and CMR perfusion are not as well
tudied, RNI and stress echocardiography have robust
odies of evidence to support their use. The overwhelming
ajority of final ratings of cardiac RNI and stress echocar-
iography were concordant for similar clinical indications.
owever, a few of the final scores and rating categories
eported in this document differ from those previously
ublished for stress echocardiography (2). Readers should
ote, however, that the categorical summaries tend to
ccentuate differences that sometimes are slight. For exam-
le, small fluctuations in a median rating (e.g., 4 versus 3)
ill cause an indication to switch appropriate use categories
from uncertain to inappropriate). There are several poten-
ial reasons for these discordant occurrences. The most
ikely reason for this is a simple variation in the ratings by
he different panel members, whether due to different
ackgrounds levels and types of clinical experience or
nterpretations of data. The RAND process has docu-
ented that the interpretation of the literature by different
ets of experts can yield slightly different final ratings (5).
nconsistency in wording of indications for the cardiac RNI tnd stress echocardiography panels has also likely contrib-
ted to differences in the ratings of some scenarios. Finally,
rue differences in the data reported in the literature regard-
ng the modalities might explain some of the discordance.
.1. Cardiac Radionuclide Imaging
ppropriate Use Criteria
he clinical scenarios included in this report were designed
o reflect the most common and important potential appli-
ations for cardiac RNI. After the preparation of a draft
anuscript by the writing group and extensive review from
xternal editors and then by the technical panel itself, the
esult is a set of scenarios that clearly define patient-specific
pplications.
The primary objective of this report is to provide guid-
nce regarding the suitability of cardiac RNI for diverse
linical scenarios. As with previous AUC documents, con-
ensus among the raters was desirable, but an attempt to
chieve complete agreement within this diverse panel would
ave been artificial and was not the goal of the process. Two
ounds of ratings with substantial discussion among the
echnical panelists concerning the ratings did lead to some
onsensus among panelists. However, further attempts to
rive consensus would have diluted true differences in
pinion among panelists and therefore was not undertaken.
Among the 67 indications, 33 were classified as appro-
riate, while uncertain and inappropriate designations were
ssigned for 9 and 25 indications, respectively.
To facilitate implementation of these AUC, an algorithm
s presented in Figure 1, which presents a hierarchy of
otential test ordering based on clinical presentation. The
urpose of this algorithm is to help avoid situations in which
he AUC failed to follow the true clinical reasons for test
rdering, such as using an indication designed for assess-
ent of chest pain even when a patient may have already
ndergone revascularization or a prior imaging procedure.
Table 1 focused on the diagnostic value of RNI. As
hown in Figure 2, patients with an ischemic equivalent,
onsisting of symptoms associated with CAD or ECG
ndings, were divided based on the likelihood of ischemic
eart disease. RNI was appropriate in patients with an
ntermediate or high likelihood of CAD, as it was in
atients with a low likelihood if they were unable to exercise
r had an uninterpretable ECG. The technical panel spe-
ifically decided to incorporate Thrombolysis In Myocardial
nfarction (TIMI) scores into the indications describing
cute chest pain syndromes to provide a more comprehen-
ive risk assessment model and one that was consistent with
ontemporary literature. The technical panel somewhat
rbitrarily selected a TIMI score of 2 as a threshold value for
ow and high risk, as the actual value is currently not defined
n guidelines (20). Regarding troponin values, “peak” tro-
onin was used for the indication, implying more than 1
ample was obtained, and serial testing was performed prior
o a stress procedure. The technical panel felt it was best not
o provide a cutoff value for troponin elevation, but instead
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June 9, 2009:2201–29 Appropriate Use Criteria for Cardiac Radionuclide Imagingecommended referring to the assay’s definition of the “bor-
erline/equivocal/slightly elevated” category, as this would
reserve the “possible ACS” definition. For patients with a
uspected ACS, RNI was considered appropriate irrespec-
ive of the TIMI score or whether or not their troponin
evels were elevated. These potential discriminators were
igure 2. Potential Applications for Chest Pain
atients with an ischemic equivalent, consisting of symptoms associated with CAD o
igure 1. Hierarchy of Potential Test Ordering
ased on Clinical Presentation
or those patients who may be classified into more than 1 of the clinical indication
ables and/or algorithms, this flow chart places clinical conditions into a hierarchy
o aid in assessing appropriateness for radionuclide imaging. *Symptomatic
atients who are being considered for a preoperative evaluation for noncardiac sur-
ery should begin down the algorithm as if “No.”or patients with a suspected ACS, RNI was appropriate irrespective of the TIMI score or wncluded by the writing group, but were not felt to assist
NI utilization by the technical panel.
Table 2 primarily focused on the asymptomatic patient
nd is reflected in Figure 3. RNI was felt to be appropriate
nly in high CHD risk patients, and in those with inter-
ediate CHD risk with an uninterpretable ECG, RNI was
onsidered “uncertain.” The presence of unexplained tropo-
in elevation, newly diagnosed heart failure, and ventricular
achycardia were appropriate indications for RNI, but RNI
as of uncertain appropriateness in the setting of atrial
brillation. This latter category was not divided by CHD
isk per the technical panel’s request and was based on
ecent data (21). The appropriate use of RNI in the setting
f syncope was dependent on CHD risk.
The use of RNI in patients with prior test results was
resented in Table 3. As shown in Figure 4, RNI was
nappropriate if prior test results were known, except when
erformed more than 2 years later and only if an abnormal
tudy was previously present or if the patient was at
ntermediate or greater CHD risk. In those circumstances,
NI use was “uncertain.” When new or worsening symp-
oms were present, RNI was appropriate with prior abnor-
al results, but was uncertain if the prior study was normal.
egarding patients with prior coronary artery calcium
CAC) scoring, RNI was inappropriate in those with a
AC score less than 100. However, RNI was appropriate in
hose with a CAC score greater than 400 or between 100
nd 400 with intermediate CHD risk and was uncertain in
hose with a CAC score between 100 and 400 and low-
ntermediate CHD risk. Finally, a low-risk Duke treadmill
core derived from a prior exercise study was felt to be an
nappropriate indication for RNI.
findings, were divided based on the likelihood of CAD. If patients had an interme-r ECG
iate or high likelihood for CAD, RNI was appropriate. RNI was also appropriate for patients at low likelihood if they were unable to exercise or had an uninterpretable ECG.hether or not their troponin levels were elevated.
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25) mandated a major revision of the original SPECT MPI
riteria (1). Table 4 lists the clinical scenarios and the
ppropriate use ratings, with Figure 5 summarizing these
cores. Overall, RNI was felt to be inappropriate for
reoperative risk assessment except in the setting of inter-
igure 3. Potential Applications for Asymptomatic* Patients
nly in high CHD risk patients was RNI felt to be appropriate, although those with in
ope did not alter the appropriateness of patients separate from their CHD risk, with
omatic patients exhibiting the following clinical indications are appropriate (or uncer
iagnosed heart failure with LV systolic dysfunction without ischemic equivalent who
riate); 2) ventricular tachycardia (Appropriate); 3) elevated troponin without addition
Uncertain). †Includes diabetes mellitus or the presence of other clinical atheroscler
rtery disease, and other likely forms of clinical disease (e.g., renal artery disease).
igure 4. Prior Test Results*
hen new or worsening symptoms were present, RNI was appropriate if prior abnorm
ropriate when no or stable symptoms were present if prior test results were known
iously present or if the patient was at intermediate or greater CHD risk. In those cir
ncertain in the following 2 scenarios: 1) Coronary Angiography: coronary stenosis or anato
quivocal, borderline, or discordant stress testing where obstructive CAD remains a conceediate risk or vascular surgery when at least 1 risk factor is
resent and the patient has a limited functional capacity.
Following an acute ACS, it was felt that RNI was inappro-
riate within 3 months after ACS except in those patients
here a prior coronary angiogram had not been performed.
ollowing revascularization with PCI or CABG in a more
iate CHD risk with an uninterpretable ECG were uncertain. The presence of syn-
sk patients being inappropriate and high-risk patients being appropriate. *Asymp-
or RNI and do not require risk assessment by either step: 1) new-onset or newly
not had a prior CAD evaluation AND have no planned coronary angiography (Appro-
ence of acute coronary syndrome (Appropriate); 4) new-onset atrial fibrillation
sease, including peripheral arterial disease, abdominal aortic aneurysm, carotid
ults were present, but was uncertain if the prior study was normal. RNI was inap-
t when performed more than 2 years later, and only if an abnormal study was pre-
ances, RNI use was “uncertain.” *RNI is appropriate if prior test results weretermed
low-ri
tain) f
have
al evidal res
, excep
cumstmic abnormality of uncertain significance; OR 2) Prior Noninvasive Evaluation:
rn.
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June 9, 2009:2201–29 Appropriate Use Criteria for Cardiac Radionuclide Imaginghronic setting, recurrence of symptoms or the presence of
uspected incomplete revascularization were felt to be appro-
riate indications. The revascularization procedure and the
ime elapsed before considering RNI resulted in a variety of
ppropriate use ratings, as depicted in Table 6 and Figure 6.
oth the writing group and the technical panel spent a great
eal of time deliberating the issue of whether to incorporate a
istinction between the presence or absence of symptoms prior
o revascularization into the indications, as patients may have
ndergone testing in the setting of silent ischemia. The writing
roup initially elected to keep prerevascularization symptom-
tology as a discrimination point within the indication, in
eeping with the prior SPECT MPI criteria and those for
tress echocardiography. However, the technical panel ulti-
ately decided to remove the distinction due to the lack
ufficient evidence that this qualification was relevant.
Table 8 focuses on ventricular function assessment, not
PI, in an effort to delineate appropriateness of gated
PECT, first pass radionuclide angiography (FP RNA),
nd equilibrium radionuclide angiography. The routine use
f FP RNA imaging was deemed inappropriate but was
ncertain when used in a selective fashion, such as for those
atients with suspected multivessel coronary disease.
Several changes were present when comparing the orig-
nal SPECT MPI criteria to the new RNI AUC. Specifi-
ally, indications 26 and 28 are now “uncertain” compared
ith the previous designation of “appropriate”—these
hanges likely reflect increased knowledge and/or differing
echnical panel composition. Additionally, indication 32 has
igure 5. Perioperative Evaluation
NI was felt to be inappropriate for preoperative risk assessment except in the setti
atient has poor or unknown functional capacity. Additionally, patients who are asym
arization in the setting of intermediate risk or vascular surgery were also rated as in
re, cerebrovascular disease, diabetes mellitus (requiring insulin), or renal insufficienhanged from uncertain to appropriate. r.2. Application of Criteria
here are many potential applications for AUC. Clinicians
ould use the ratings for decision support or an educational tool
hen considering the need for cardiac RNI. Moreover, these
riteria could be used to facilitate discussion with patients
nd/or referring physicians about the need for cardiac RNI.
acilities and payers may choose to use these criteria either
rospectively in the design of protocols or preauthorization
rocedures or retrospectively for quality reports. It is hoped
hat payers would use these criteria as the basis for the
evelopment of rational payment management strategies.
It is expected that services performed for appropriate
ndications will be considered reimbursable. In contrast,
ervices performed for inappropriate indications should
ikely require additional documentation to justify reimburse-
ent because of the unique circumstances or the clinical
rofile that must exist in such a patient. It is critical to
mphasize that the writing group, technical panel, AUC
orking Group, and clinical community do not believe an
ncertain rating is grounds to deny reimbursement for
ardiac RNI. Rather, uncertain ratings are those where the
vailable data vary and many other factors exist that may
ffect the decision to perform or not perform cardiac RNI.
he opinions of the technical panel often varied for these
ndications, reflecting that additional research is needed.
ndications with high clinical volume that are rated as
ncertain identify important areas for further research.
In conclusion, this document represents the current
nderstanding of the clinical benefit of cardiac RNI with
intermediate risk or vascular surgery when at least 1 risk factor is present and the
tic up to 1 year postnormal catheterization, noninvasive test, or previous revascu-
priate for RNI. *History of ischemic heart disease, compensated or prior heart fail-
eatinine 2.0).ng of
ptoma
approespect to health outcomes and survival. It is intended to
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Appropriate Use Criteria for Cardiac Radionuclide Imaging June 9, 2009:2201–29rovide a practical guide to clinicians and patients when
onsidering cardiac RNI. As with other AUC documents,
ome of these ratings will require research and further
valuation to provide the greatest information and benefit to
linical decision making. Finally, it will be necessary to
eriodically assess and update the indications and criteria as
echnology evolves and new data and field experience
ecomes available.
ppendix A: Additional Cardiac Radionuclide
maging Definitions
ngina: as defined by the ACC/AHA Guidelines on
xercise Testing (7)
Typical Angina (Definite):
1. Substernal chest pain or discomfort that is
2. provoked by exertion or emotional stress and
3. relieved by rest and/or nitroglycerin (22).
Atypical Angina (Probable): Chest pain or discomfort
that lacks one of the characteristics of definite or typical
angina (22).
Nonanginal Chest Pain: Chest pain or discomfort that
meets one or none of the typical angina characteristics.
CS: As defined by the ACC/AHA Guidelines for the
anagement of Patients With ST-Elevation Myocardial
igure 6. Postrevascularization
ollowing revascularization with PCI or CABG in a more chronic (3 months) set-
ing, recurrence of symptoms or the presence of suspected incomplete revascular-
zation were felt to be appropriate indications for RNI. For asymptomatic patients
ess than 2 years after a PCI, RNI was rated inappropriate. For asymptomatic
atients at less than 5 years after CABG or those at greater than or equal to 2
ears after PCI, RNI was rated uncertain. If CABG was performed more than 5 years
go, RNI is appropriate. *Assumes that additional revascularization is feasible.nfarction: patients with an ACS include those whose
m
Ilinical presentations cover the following range of diagnoses:
nstable angina, myocardial infarction without ST elevation
NSTEMI), and myocardial infarction with ST elevation
STEMI) (23).
valuating Perioperative Risk for Noncardiac Surgery
ETHOD FOR DETERMINING PERIOPERATIVE RISK
ee Figure A1, “Stepwise Approach to Perioperative Car-
iac Assessment,” from the ACC/AHA 2007 Perioperative
uidelines (18). Based on the algorithm, once it is deter-
ined that the patient does not require urgent surgery, the
linician should determine the patient’s active cardiac con-
itions (see Table A1) and/or perioperative risk predictor
see Table A2). If any active cardiac conditions and/or
ajor risk predictors are present (see Tables A1 and A2),
igure A1 suggests consideration of coronary angiography
nd postponing or canceling noncardiac surgery. Once
erioperative risk predictors are assessed based on the
lgorithm, then the surgical risk and patient’s functional
tatus should be used to establish the need for noninvasive
esting.
hrombolysis In Myocardial Infarction Risk Scores
he TIMI risk score (21) is a simple tool composed of 7
1-point) risk indicators rated on presentation (Table A3).
he composite end points (all-cause mortality, new or
able A1. TIMI Risk Score for Unstable Angina/
on–ST-Elevation Myocardial Infarction
Condition Examples
nstable coronary syndromes Unstable or severe angina* (CCS class III
or IV)†
Recent MI‡
ecompensated HF
(NYHA functional class IV;
worsening or new-onset HF)
ignificant arrhythmias High-grade atrioventricular block
Mobitz II atrioventricular block
Third-degree atrioventricular heart block
Symptomatic ventricular arrhythmias
Supraventricular arrhythmias (including
atrial fibrillation) with uncontrolled
ventricular rate (HR greater than
100 bpm at rest)
Symptomatic bradycardia
Newly recognized ventricular tachycardia
evere valvular disease Severe aortic stenosis (mean pressure
gradient greater than 40 mm Hg,
aortic valve area less than 1.0 cm2,
or symptomatic)
Symptomatic mitral stenosis
(progressive dyspnea on exertion,
exertional presyncope, or HF)
According to Campeau (24). †May include “stable” angina in patients who are unusually
edentary. ‡The American College of Cardiology National Database Library defines recent MI as
ore than 7 days but less than or equal to 1 month (within 30 days). Reprinted from Anderson
t al. (25).
CCS indicates Canadian Cardiovascular Society; HF, heart failure, HR, heart rate; MI,
yocardial infarction; NYHA, New York Heart Association; and TIMI, Thrombolysis In Myocardial
nfarction.
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June 9, 2009:2201–29 Appropriate Use Criteria for Cardiac Radionuclide Imagingecurrent MI, or severe recurrent ischemia prompting ur-
ent revascularization within 14 days) increase as the TIMI
isk score increases. The model remained a significant
redictor of events and test sensitivity and was relatively
naffected/uncompromised by missing information, such as
nowledge of previously documented coronary stenosis of
0% or more. The model’s predictive ability remained intact
ith a cutoff of 65 years of age.
The TIMI risk score is determined by the sum of the
resence of 7 variables at admission; 1 point is given for each
f the following variables: age 65 years or older; at least 3
able A2. Perioperative Clinical Risk Factors*
History of ischemic heart disease
History of compensated or prior heart failure
History of cerebrovascular disease
Diabetes mellitus (requiring insulin)
Renal insufficiency (creatinine greater than 2.0)
igure A1. Stepwise Approach to Perioperative Cardiac Assessme
ardiac evaluation and care algorithm for noncardiac surgery based on active clinica
f age or greater. *See Table A1 for active clinical conditions. †Please note that the
nvasive testing is not useful for patients with no clinical risk factors undergoing inte
ot useful for patients undergoing low-risk noncardiac surgery (Level of Evidence: C).
efore surgery in specific patients with risk factors if it will change management. Cli
etes mellitus, renal insufficiency, and cerebrovascular disease. ¶Consider periopera
idity/mortality. Reprinted from the recommendations from the ACC/AHA 2007 GuidAs defined by the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and
are for Noncardiac Surgery (18). Note that these are not standard CAD risk factors.
R
Cisk factors for CAD; prior coronary stenosis of 50% or
ore; ST-segment deviation on ECG presentation; at least
anginal events in prior 24 hours; use of aspirin in prior 7
ays; and elevated serum cardiac biomarkers. Prior coronary
able A3. Active Cardiac Conditions for Which the Patient
hould Undergo Evaluation and Treatment Before Noncardiac
urgery (Class I, Level of Evidence: B)
TIMI Risk Score
All-Cause Mortality, New or Recurrent
MI, or Severe Recurrent Ischemia
Requiring Urgent Revascularization
Through 14 Days After Randomization, %
0–1 4.7
2 8.3
3 13.2
4 19.9
5 26.2
6–7 40.9
itions, known cardiovascular disease, or cardiac risk factors for patients 50 years
ACC/AHA Guidelines for Perioperative Cardiac Assessment recommend that non-
te-risk noncardiac surgery (Level of Evidence: C) and that noninvasive testing is
Table A2 for list of clinical risk factors. §Noninvasive testing may be considered
sk factors include ischemic heart disease, compensated or prior heart failure, dia-
eta blockade for populations in which this has been shown to reduce cardiac mor-
on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery (18).nt
l cond
2007
rmedia
‡See
nical ri
tive beprinted from the recommendations from the ACC/AHA 2007 Guidelines on Perioperative
ardiovascular Evaluation and Care for Noncardiac Surgery (18).
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Appropriate Use Criteria for Cardiac Radionuclide Imaging June 9, 2009:2201–29tenosis of 50% or more was relatively unaffected/
ncompromised by missing information and remained a
ignificant predictor of events.
Low-Risk TIMI Score: TIMI score less than 2‡
High-Risk TIMI Score: TIMI score greater than or
equal to 2
CG—Uninterpretable
efers to ECGs with resting ST-segment depression
greater than or equal to 0.10 mV), complete LBBB,
reexcitation (Wolff-Parkinson-White Syndrome), or
aced rhythm.
ppendix B: Additional Methods
ee Section 2, Methods, for a description of panel selection,
ndication development, scope of indications, and rating
rocess.
elationships With Industry
he ACCF and its partnering organizations rigorously
void any actual, perceived, or potential conflicts of interest
hat might arise as a result of an outside relationship or
ersonal interest of a member of the technical panel.
pecifically, all panelists are asked to provide disclosure
tatements of all relationships that might be perceived as
eal or potential conflicts of interest. These statements were
eviewed by the AUC Working Group, discussed with all
embers of the technical panel at the face-to-face meeting,
nd updated and reviewed as necessary. A table of disclo-
ures by the technical panel and oversight working group
embers can be found in Appendix C.
iterature Review
he technical panel members were asked to refer to the
elevant guidelines for a summary of the relevant literature,
uideline recommendation tables, and reference lists pro-
ided for each indication table when completing their
atings (Online Appendix at http://content.onlinejacc.org/
gi/content/full/j.jacc.2009.02.013).
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